HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A double-blind crossover study comparing the safety and efficacy of three weeks of Flu/Sal 250/50 bid plus albuterol 180 ug prn q4 hours to Flu/Sal 250/50 bid plus albuterol/Ipratropium bromide 2 puffs prn q4 hours in patients with chronic obstructive pulmonary disease.

Abstract
The Federal Drug Administration (FDA) approved the use of Fluticasone 250 microg/Salmeterol 50 microg 1 puff bid for maintenance therapy in patients with COPD associated with chronic bronchitis. Short-acting beta agonists (SABA) have been the recommended rescue medication; however, previous studies have shown that combination short-acting Albuterol (alb) /Ipratropium bromide (IB) has superior bronchodilator properties to albuterol alone in patients with COPD. The safety and efficacy of Albuterol compared to Albuterol/Ipratropium bromide as rescue medications for COPD patients on maintenance combination therapy of ICS/LABA has not been evaluated. Double-blind randomized crossover trial with COPD subjects receiving Fluticasone/ Salmeterol 500 microg/50 microg (Flu/Sal) 1 puff twice daily and 2 puffs of Albuterol Sulfate (90 microg micrograms per inhalation) or 2 puffs of Albuterol (90 microg/puff and Ipratropium Bromide 18 microg/puff. Either Albuterol Sulfate (90 micrograms/puff) or Alb (90 micrograms/puff)/IB used prn for 3 weeks before crossing over to the other rescue formulation. This is a non-inferiority study where safety and efficacy outcomes were serially assessed, including adverse events, Baseline (BDI)/Transition Dyspnea Index (TDI), St. George Respiratory Questionnaire (SGRQ), SF36, diary cards, 24-hour cardiac monitoring, potassium and glucose levels and other adverse events. Twenty subjects completed the study. The mean age was 62.5 (+/- 14.5); 12 were males. The mean baseline FEV(1) (range) was 1.12 L (0.56-1.67) or 40.6 (21-65)% predicted. There were no statistically significant differences between either rescue inhaler formulation with regard to measures neither of lung function or dyspnea nor in terms of safety parameters of cardiac monitoring, glucose and potassium levels and other adverse events. SABA and combination SABA/Ipratropium bromide are equally safe and efficacious as rescue inhalers for patients on combination Fluticasone 500 microg/Salmeterol 50 microg.
AuthorsRon Balkissoon, Barry Make
JournalCOPD (COPD) Vol. 5 Issue 4 Pg. 221-7 (Aug 2008) ISSN: 1541-2563 [Electronic] England
PMID18671147 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Androstadienes
  • Bronchodilator Agents
  • Salmeterol Xinafoate
  • Fluticasone
  • Ipratropium
  • Albuterol
Topics
  • Administration, Inhalation
  • Aged
  • Albuterol (administration & dosage, analogs & derivatives)
  • Androstadienes (administration & dosage)
  • Bronchodilator Agents (administration & dosage)
  • Cross-Over Studies
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Fluticasone
  • Follow-Up Studies
  • Humans
  • Ipratropium (administration & dosage)
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Probability
  • Pulmonary Disease, Chronic Obstructive (diagnosis, drug therapy, mortality)
  • Reference Values
  • Respiratory Function Tests
  • Risk Assessment
  • Salmeterol Xinafoate
  • Severity of Illness Index
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: